1. Introduction {#sec1}
===============

*Trichomonas vaginalis* (*T. vaginalis*) is the most common curable sexually transmitted infection (STI), and despite high prevalence rates ranging from 5--75%, and adverse health consequences such as pelvic inflammatory disease and adverse pregnancy outcomes, it has received little attention globally \[[@B1]\]. Sub-Saharan Africa continues to bear a disproportionate burden of the HIV disease with an estimated 22.5 million people living with HIV \[[@B2]\] and *T. vaginalis* has been shown to increase the odds of HIV acquisition between 1.5-fold and 3-fold \[[@B3], [@B4]\]. Dual use of efficacious contraceptives and condoms continues to be encouraged to prevent unwanted pregnancies and the high rates of HIV and STIs; however, dual use continues to be uncommon, especially among stable unions.

The use of hormonal contraception (HC) and especially injectable contraceptives (ICs) is gaining popularity in Sub-Saharan Africa \[[@B5]\], and the two latest Ugandan demographic and health survey (DHS) show an increase in use of HCs among currently married women aged 15 to 49 years from 13.4% in 2005/6 \[[@B6]\] to 19.7% in 2011 \[[@B7]\]. Given that *T. vaginalis* is highly asymptomatic in females and their male partners and rates of reinfection are consequently high, efforts need to focus on integration of *T. vaginalis* screening and prevention in family planning, reproductive health, and HIV care centres as syndromic management alone may not be enough.

Studies suggested that women using HC and especially progesterone-only contraception, may be at increased risk for HIV acquisition and other STIs. A systematic review found that injectable contraceptives (IC) increased risk of HIV transmission \[[@B8], [@B9]\], by some, but not all, studies. With the lack of consistent evidence regarding the association of HC and HIV infection, the current WHO guidelines recommend that women at high risk for HIV infection can use any HC, with encouragement of concomitant use of condoms \[[@B10]\].

A recent examination of the association of HC (Combined Oral Contraceptives-COCs and DMPA) and risk of STIs found no association between *T. vaginalis* and COCs in a prospective study among sex workers in Kenya but a reduced risk associated with Norplant \[[@B4]\]. Results from studies assessing impact of DMPA use and *T. vaginalis* were mixed as some studies found no association \[[@B12], [@B13]\], while others found a decreased risk \[[@B12], [@B14]\].

Of the studies that did find a decrease in the risk of *T. vaginalis* associated with DMPA, none were population based studies; one was a prospective study of sex workers in Kenya \[[@B12]\] and another on women attending family planning clinics in South Africa \[[@B14]\]. There are insufficient data about the determinants of *T. vaginalis* among women from rural community based settings. Given the popularity of HC among African women, understanding the impact of HC on STI risk is important.

The purpose of our study was to assess determinants of *T. vaginalis* and, specifically, the impact of HIV infection and HC on incidence of *T. vaginalis* among women from rural Rakai, Uganda.

2. Methods {#sec2}
==========

Rural Rakai district located in southwest Uganda is the site of a prospective open cohort study called the Rakai Community Cohort Study (RCCS). We conducted retrospective analyses of data from two rounds of RCCS conducted in 2011 and 2012 to assess risk factors of *T. vaginalis* among consenting women aged 15 to 49 years resident in 50 communities.

Details have been described previously \[[@B15], [@B16]\], but, briefly, detailed information is collected on RCCS participants annually on sociodemographic, sexual behaviour, and contraceptive use. In addition, biological specimens are collected to test for HIV and STIs such as *T. vaginalis*, bacterial vaginosis, and syphilis.

Biological samples were collected in the home after the interview. HIV status was determined from venous blood using two different enzyme immunoassays (Vironostika HIV-1, OrganonTeknika, Charlotte, North Carolina, USA, and Cambridge Biotech, Worcester, Massachusetts, USA), with Western blot (HIV-1 WB Bio-Merieux-Vitek, St Louis, Missouri, USA) confirmation of all discordant EIAs and all HIV seroconverters. Syphilis was screened for in each round using the nontreponemal TRUST (Toluidine Red Unheated Serum Test, New Horizons, Columbia, MD, USA), with positive samples confirmed with the use of *Treponema pallidum*haemagglutination (Sera-Tek, Fujirebio, Tokyo, Japan). Two self-collected vaginal swabs were obtained from all consenting women in the cohort. One swab was inoculated into a *Trichomonas vaginalis (T. vaginalis)* culture kit (InPouch TV, BioMed Diagnostics, San Jose, CA, USA). In order to assess incidence of *T. vaginalis*, all women with complete information on *T. vaginalis*and HIV serostatus from rounds 14 (2010-11) and 15 (2011-12) were included in these analyses. The second swab was gram-stained and read for bacterial vaginosis by the quantitative, morphological Nugent scoring system.

Covariates considered in our analyses were (i) age stratified as less than 20 years, 20--29 years, 30--39 years, and 40+ years, (ii) marital status categorized as never married, currently married, or previously married and among married, women in monogamous versus polygamous unions, (iii) education classified as none, primary, and secondary or more, (iv) religion classified as Catholic/Protestant, Saved/Pentecostal, or other, (v) number of sexual partners in the past 12 months classified as 1 or 2 or more, (vi) socioeconomic status (SES) based on the dwelling construction materials with high SES if modern construction materials (iron/tiles, cement) were used, (vii) Nugent score of 0--3, 4--6, and 7--10 (BV), (viii) syphilis result, and (ix) HIV infection. Four different variables were created for contraceptive use exposure (Tables [2](#tab2){ref-type="table"}(a)--[2](#tab2){ref-type="table"}(d)). (i) No HC/no condoms (reference group) and the exposure group consisted of 2 groups of women: women who used HC only and women who used condoms only; (ii) no HC/no condoms (reference group) and exposure was 4 groups of women: DMPA only, COC only, implants only, and condoms only; (iii) they consistently used no contraception method at baseline and follow-up (reference group) and exposure was 4 groups of women; they consistently used HCs only at baseline and follow-up, initiated HCs at follow-up, discontinued HCs at follow-up, and consistently used condoms only at baseline and follow-up;(iv) they consistently used no contraception method at baseline or follow-up (reference group) and exposure groups were women who consistently used DMPA only at baseline and follow-up, consistently used COCs at baseline and follow-up, and consistently used implants only at baseline and follow-up and other contraceptive use category (includes all women who were not included in the categories above for this table).

Statistical tests used were chi-squared analyses for comparison between groups defined by contraceptive exposure. The incidence of *T. vaginalis* was determined as the number of new *T. vaginalis*-positive women at the follow-up visit, estimated per 100 person-years (py). *T. vaginalis* infection was assumed to have occurred at mid-interval between surveys. The association between HC and incidence *T. vaginalis* was assessed by use of incidence rate ratios (IRR) through the Poisson regression models. Subanalyses were done to determine the effect of each HC method on T. vaginalis incidence as well as impact of continuation of use between the two rounds of follow-up. All variables in the bivariate analyses with *P* \< 0.15, potential confounders, or variables with an IRR ≥2.0 or ≤0.5 were included in the adjusted model to obtain independent effects of HC use on incidence *T. vaginalis*. All variables in the multivariate model were assessed for collinearity using the variance inflation factor (VIF) and variables found to be highly correlated were excluded from the multivariate analyses. Covariates in all the analyses included age, marital status, education, social-economic status (SES), condom use, and other STIs. The interaction between HC use and HIV status was conducted and tested for statistical significance using the Wald-test. Model goodness of fit was tested using log-likelihood tests. All statistical analyses were conducted using STATA software package version 12.0 (College Station, Texas, USA).

The studies were approved by Institutional Review Boards in Uganda (the Scientific and Ethics Committee of the Uganda Virus Research Institute and the Uganda National Council of Science and Technology) and the United States (Western IRB, Olympia, Washington, and the Johns Hopkins University, School of Public Health).

3. Results {#sec3}
==========

Overall, 2,374 sexually active, consenting women aged 15 to 49 years with complete data on *T. vaginalis* and HIV infection status between round 14 (2010-2011) and round 15 (2011-2012) were included in these analyses. All women in this analyses tested negative for*T. vaginalis* at baseline.

The primary outcome of interest was incidence of *T. vaginalis* associated with hormonal contraceptive (HC) use. The analyses assessed risk of *T. vaginalis* associated with overall hormonal contraception (HC) use as well as stratified by type of HC used: Depo-Provera (DMPA), combined oral contraceptives (COCs), and implants (Norplant). All adjusted analyses controlled for potential confounders such as infection with other STIs such as bacterial vaginosis (BV) and syphilis, HIV infection, and number of sexual partners in the past 12 months. In addition, the risk for *T. vaginalis* was assessed by consistency and continuation of HC use between the two rounds of follow-up.

In this analysis, which excludes other modern contraceptive methods, the overall 12 months prevalence of use of HC, was 34.9% (829/2374). Among HC users, the most commonly used types were DMPA (81.3%), COCs (15.1%), or Norplant (3.7%). The proportion of women who tested positive for *T. vaginalis* at the end of the 12-month follow-up visit was 4.0% (96/2374), resulting in an incidence of 2.4/100 py (1.90, 3.25). A total of 206 *T. vaginalis*-positive women at baseline were excluded from the analyses as our goal was to examine incidence of *T. vaginalis* associated with HC use. These initially *T. vaginalis*-negative women had lower risk characteristics than women with baseline prevalent *T. vaginalis*. For example, the proportions with 2 or more sex partners were 1.4% among the baseline *T. vaginalis*-negative compared with 5.8% among the baseline *T. vaginalis*-positive participants (*P* \< 0.01).

[Table 1](#tab1){ref-type="table"} provides a summary of baseline characteristics by contraceptive use stratified by contraceptive use: no HC or condom use, HC use (DMPA, COCs, Norplant), and condom use alone. A significantly higher proportion of HC users are between 20 and 39 years of age, whereas a higher proportion of individuals less than 20 years were condom users. Condom users were also significantly more likely to be never or previously married and HC users were significantly more likely to be currently married. Condom users were significantly less likely to have primary or higher education, and HC and condom users were significantly more likely to be classified as high socio-economic status (SES), compared to women not using HC or using condoms alone. When looking at multiple sexual partners by contraceptive use, HC users were significantly less likely to have 2 or more partners compared to women who used condoms alone or women who used neither HC nor condoms. When looking at HIV infection rates by contraceptive use, a significantly higher proportion of condom users were HIV-positive compared to women who used HC or did not use HC or condoms. There was no significant difference by religion, BV-scores, or syphilis infection by contraceptive use.

Overall, 12.8% of the women were HIV-positive 39.7% with high BV-scores (7--10) and 3.4% syphilis-positive at baseline. *T. vaginalis* incidence was significantly higher among HIV-positive (5.0/100 py) versus HIV-negative women (2.0/100 py, *P* \< 0.0001). There was no significant difference in HIV incidence rates of women who tested positive versus negative for *T. vaginalis* at follow-up (0.46/100 py and 0.50/100 py, resp.; *P* = 1.00).

Tables [2](#tab2){ref-type="table"}(a)--[2](#tab2){ref-type="table"}(d) summarize *T. vaginalis* incidence by demographic and behavioural characteristics. [Table 2](#tab2){ref-type="table"}(a) summarizes *T. vaginalis* incidence by HC or condom use. After adjusting for sociodemographic and behavioral risk factors, syphilis infection, and BV status, factors associated with an increased risk of incident *T. vaginalis*were HIV-positive (adj.IRR = 2.34, CI: 1.44, 3.78), whereas factors that decreased the risk of *T. vaginalis* were over 40 years and were having secondary or more education. [Table 2](#tab2){ref-type="table"}(b) summarizes *T. vaginalis* incidence by type of contraceptive method used. In the adjusted model, factors associated with an increased risk of incident *T. vaginalis* were using implants only (adj.IRR = 3.01, CI: 1.07, 8.49) and were HIV-positive (adj.IRR = 2.38, CI: 1.47, 3.86), and factors that decreased the risk of *T. vaginalis* were using DMPA only (adj.IRR = 0.54, CI: 0.30, 0.98), being over 40 years and having secondary or more education. [Table 2](#tab2){ref-type="table"}(c) summarizes *T. vaginalis* incidence by consistency of contraceptive use at baseline and follow-up. In the adjusted model, factors associated with an increased risk of Incident *T. vaginalis* were HIV-positive (adj.IRR = 2.36, CI: 1.44, 3.85), whereas factors associated with a decreased risk of *T. vaginalis* were discontinuing HC use at follow-up (adj.IRR = 0.30, CI: 0.09, 0.99), being over 40 years and having secondary or higher education. [Table 2](#tab2){ref-type="table"}(d) summarizes *T. vaginalis* incidence by consistency of HC use at baseline and follow-up. In the adjusted model, factors associated with an increased risk of incident *T. vaginalis* were consistently using implants only (adj.IRR = 3.13, CI: 1.08, 9.07), having 1 sexual partner compared to none (adj.IRR = 1.61, CI: 1.01, 2.55) and being HIV infected (adj.IRR = 2.52, CI: 1.56, 4.08), whereas factors associated with a decrease in the risk of *T. vaginalis* were 40 years or older and were having secondary or higher education.

When assessing the impact of HC on *T. vaginalis* incidence (Tables [2](#tab2){ref-type="table"}(a)--[2](#tab2){ref-type="table"}(d)), factors that were associated with an increased risk of *T. vaginalis* in the unadjusted analyses were use of Norplant (IRR = 2.75, CI: 1.00--7.65), having one versus no sexual partner in the past 12 months (IRR = 1.66, CI: 1.07, 2.56) and being HIV seropositive (IRR = 2.40, CI: 1.42, 4.08). Factors associated with a decrease in the incidence of *T. vaginalis* were using DMPA only in the past 12 months (IRR = 0.53, CI: 0.30--0.95), discontinuing HC during the follow-up period (IRR = 0.30, CI: 0.09--1.00), being over 40 years of age and having a secondary or higher education.

After adjusting for sociodemographic, behavioral risk factors, syphilis infection, and BV status, factors associated with increased risk of incident *T. vaginalis* infection were use of Norplant in the past 12 months (adj.IRR = 2.82, CI: 1.00, 8.0) and being HIV seropositive (adj.IRR = 2.45, CI: 1.51, 3.97). Factors associated with a decrease in the risk of *T. vaginalis* were use of DMPA in the past 12 months (adj.IRR = 0.53, CI: 0.29, 0.97), discontinuing HC in the past 12 months (IRR = 0.30, CI: 0.09--0.99), being over 40 years of age and having secondary education or higher.

Considering HC use at baseline and follow-up, the risk of *T. vaginalis* increased with consistent use of COCs (adj.IRR = 1.15, CI: 0.27, 4.97) and Norplant (adj.IRR = 2.76, CI: 0.92, 8.30) but decreased among women who consistently used DMPA (IRR = 0.58, CI: 0.27, 1.24) as shown in [Table 2](#tab2){ref-type="table"}.

Interactions between HIV infection and use of Norplant were not statistically significant.

4. Discussion {#sec4}
=============

In this longitudinal study of women in rural Uganda, use of implants (Norplant) and being HIV seropositive were associated with significantly increased incidence of *T. vaginalis*, and use of DMPA and discontinuation of hormonal contraception significantly decreased the incidence of *T. vaginalis* after controlling for HIV risk behaviors and other sexually transmitted infections (STIs) such as syphilis and bacterial vaginosis.

A number of studies have shown an increase in HIV infection associated with *T. vaginalis* \[[@B3], [@B4], [@B17]\]. Our study found similar rates of HIV incidence among women who tested positive for *T. vaginalis* at follow-up versus those who did not. However, power may be limited by the small number of seroconverters in the follow-up period. There are relatively few studies examining the effects of HIV on STI transmission and most are cross-sectional \[[@B18]\]. Although studies have not found an increase in the prevalence, incidence, persistence, or recurrence of *T. vaginalis* among women who are HIV-positive \[[@B19]\], our study found a significantly higher incidence of *T. vaginalis* among women who were HIV-positive, but the possibility of confounding due to correlated sexual behaviours cannot be excluded.

A recent review examined the association of hormonal contraception (COCs and DMPA) and risk of STIs and found that several longitudinal studies demonstrated increased risk of STIs such as chlamydia and gonorrhoea associated with DMPA and COCs \[[@B12], [@B20], [@B21]\]. The association between incidence of *T. vaginalis* and hormonal contraceptives (HC) was examined by one previous longitudinal study that found a decrease in *T. vaginalis* incidence associated with oral contraceptives, compared to women using the IUD or tubal ligation \[[@B22]\]. This study is the only one to date which has found an increase in incidence of *T. vaginalis* associated with the use of Norplant. These results are of concern given that the most recent Ugandan DHS surveys (2004/5 \[[@B6]\] and 2011 \[[@B7]\]) showed an 89% increase in the women reporting use of Norplant. Although the number of women using Norplant in our study was small, the increased Norplant use in Uganda and the potential risk associated with an increased risk of *T. vaginalis* warranted further investigation.

Studies have found that both endogenous hormones based on stage of menstrual cycle and use of HCs are associated with an increased susceptibility to STIs. Although the molecular and cellular mechanisms by which HC increases HIV/STI acquisition are not well understood, HC is believed to increase risk through alteration of immune responses \[[@B12], [@B23]\], structural changes of the genital tract \[[@B24]\], and alterations in genital flora and increased acquisition of STIs \[[@B12], [@B20], [@B21]\]. Infection with *T. vaginalis* has been shown to result in increased interactions of human cervicovaginal epithelial cells to the surface lipophosphoglycan of the parasite *T. vaginalis* which results in upregulation of cytokines and inflammatory processes in the genital tract microflora which may increase susceptibility to BV as well as HIV infection \[[@B25]\]. The reduction in the risk of *T. vaginalis* associated with DMPA found in this and other studies \[[@B12], [@B14]\] is contrary to the effect seen on other STIs. Some of the reasons hypothesized for this effect are that *T. vaginalis* possesses both specific estrogen and androgen receptors, and the androgen receptor is most closely related to the progesterone receptor. Progestins found in higher dosages in DMPA can block the androgen receptor and prevent infection of *T. vaginalis* \[[@B26]\].

The levels of unmet need for spacing and limiting fertility among Ugandan women remain high (34%) \[[@B7]\] and to achieve dual protection against STIs and HIV infection, as well as an unwanted pregnancy, couples need to use reliable contraceptives which include condoms. However, in reality, dual use is uncommon. Demographic and health surveys from 14 countries in Sub-Saharan Africa found that only 6% of youth who were currently using a condom during their last sexual act were also using a nonbarrier form of contraception \[[@B27]\], and dual use among couples in our setting was only reported by 3.7% of females and 8.3% of males. Efforts to control the spread of *T. vaginalis* need to focus on efforts to improve screening and identification of people at risk of *T. vaginalis* and how the epidemiology of this STI is modified by HIV infection.

Some of the limitations of this study were that this was a cohort study where assessments were done annually and hence we were not able to measure changes in contraceptive use as well as TV infection during the course of the past 12 months and this could have led to possible misclassification bias for exposure of contraceptive use. However, we have tried to assess contraceptive use at baseline and follow-up and consistency of contraceptive use at both rounds of follow-up to try and minimize any potential misclassification.

5. Conclusions {#sec5}
==============

*Trichomonas vaginalis* incidence is higher among women using Norplant in the past 12 months, and use of DMPA or discontinuation of hormonal contraception decreased the incidence of *Trichomonas vaginalis.*

Modification of the risk of *T. vaginalis* associated with the use of some hormonal contraceptives needs to be examined further, specifically the increase in risk associated with the use of Norplant. Studies are needed to better understand the etiology and transmission of *T. vaginalis* and strategies to control *T. vaginalis* need to focus on integration of reproductive health, STI control, and HIV care services.
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###### 

Baseline and demographic characteristics.

                                                  Total   No HC/no condom use reported   COCs/injectables/implant   Condom only   *P* value                       
  ----------------------------------------------- ------- ------------------------------ -------------------------- ------------- ----------- ------ ----- ------ ---------
  Overall                                         2374    100                            1054                       100           829         100    491   100     
   Age                                                                                                                                                             
    \<20                                          165     7                              82                         7.8           18          2.2    65    13.2   \<0.001
    20--29                                        939     39.6                           424                        40.2          367         44.3   148   30.1   
    30--39                                        951     40.1                           373                        35.4          382         46.1   196   39.9   
    40+                                           319     13.4                           175                        16.6          62          7.5    82    16.7   
   Marital status                                                                                                                                                  
    Never married                                 212     8.9                            59                         5.6           39          4.7    114   23.2   \<0.001
    Currently married                             1887    79.5                           895                        84.9          728         87.8   264   53.8   
     Monogamous                                   1500    79.3                           721                        80.6          575         79     204   77.3   
     Polygamous                                   387     20.7                           174                        19.4          153         21     60    22.7   
    Previously married                            275     11.6                           100                        9.5           62          7.5    113   23     
   Education                                                                                                                                                       
    None                                          102     4.3                            58                         5.5           24          2.9    20    4.1    \<0.001
    Primary                                       1426    60.1                           672                        63.8          488         58.9   266   54.2   
    Secondary or more                             846     35.6                           324                        30.7          317         38.2   205   41.8   
   Religion                                                                                                                                                        
    Other                                         328     13.8                           154                        14.6          114         13.8   60    12.2   0.122
    Catholic/Protestant                           1977    83.3                           860                        81.6          697         84.1   420   85.5   
    Saved/Pentecostal                             69      2.9                            40                         3.8           18          2.2    11    2.2    
   Nonmarital sexual partners in last 12 months                                                                                                                    
    0                                             1835    77.3                           880                        83.5          719         86.7   236   48.1   \<0.001
    1                                             506     21.3                           167                        15.8          105         12.7   234   47.7   
    2+                                            33      1.4                            7                          0.7           5           0.6    21    4.3    
   Social-economic status                                                                                                                                          
    High                                          1311    55.2                           518                        49.1          502         60.6   291   59.3   \<0.001
    Middle                                        722     30.4                           352                        33.4          226         27.3   144   29.3   
    Low                                           341     14.4                           184                        17.5          101         12.2   56    11.4   
   HIV status                                                                                                                                                      
    Negative                                      2069    87.2                           961                        91.2          752         90.7   356   71.5   \<0.001
    Positive                                      305     12.8                           93                         8.8           77          9.3    135   28.5   
   BV-scores                                                                                                                                                       
    0--3                                          1093    46                             475                        45.1          386         46.6   232   47.3   0.316
    4--6                                          339     14.3                           145                        13.8          132         15.9   62    12.6   
    7--10                                         942     39.7                           434                        41.2          311         37.5   197   40.1   
   Syphilis result                                                                                                                                                 
    Negative                                      2300    96.9                           1020                       96.8          805         97.1   475   96.7   0.901
    Positive                                      74      3.1                            34                         3.2           24          2.9    16    3.3    

###### 

\(a\) *T. vaginalis* incidence by demographic and behavioral characteristics (HC or condom use). (b) *T. vaginalis* incidence by demographic and behavioral characteristics (type of contraception used). (c) *T. vaginalis* incidence by demographic and behavioral characteristics (consistency of contraceptive use at baseline and follow-up). (d) *T. vaginalis* incidence by demographic and behavioral characteristics (consistency of HC methods used).

                                                  *N*    Incident *T. vaginalis n*/PY   Incidence/100 py   Unadj.IRR 95% CI      Adj.IRR 95% CI
  ----------------------------------------------- ------ ------------------------------ ------------------ --------------------- ---------------------
  Overall                                         2374   96/3924.6                      2.4                                       
   HC use in last 12 months                                                                                                       
    No HC/no condom                               1054   45/1733.2                      2.60               1.00                  1.00
    HC                                            829    24/1366.2                      1.8                0.68 (0.41--1.11)     0.71 (0.43--1.17)
    Condoms only                                  491    27/825.2                       3.3                1.3 (0.78--2.03)      0.98 (0.58--1.67)
   Age                                                                                                                            
    \<20                                          165    11/277.7                       4.0                1.00                  1.00
    20--29                                        939    40/1566.3                      2.6                0.64 (0.33--1.26)     0.71 (0.35--1.44)
    30--39                                        951    37/1565.8                      2.4                0.60 (0.30--1.17)     0.58 (0.28--1.18)
    40+                                           319    8/514.8                        1.6                0.39 (0.16--0.98)∗    0.29 (0.11--0.74)∗
   Marital status                                                                                                                 
    Currently married                             1887   69/3106.7                      2.2                1.00                   
    Previously married                            275    14/459.8                       3.0                1.37 (0.77--2.43)      
    Never married                                 212    13/358.0                       3.6                1.63 (0.90--2.96)      
   Education                                                                                                                      
    None                                          102    8/172.3                        4.6                1.00                  1.00
    Primary                                       1426   67/2359.2                      2.8                0.61 (0.29--1.27)     0.64 (0.30--1.34)
    Secondary or more                             846    21/1393.0                      1.5                0.32 (0.14--0.73)∗∗   0.32 (0.14--0.74)∗∗
   Nonmarital sexual partners in last 12 months                                                                                   
    0                                             1835   64/3016.5                      2.1                1.00                  1.00
    1                                             506    30/851.7                       3.5                1.66 (1.07--2.56)∗∗   1.44 (0.89--2.33)
    2+                                            33     2/56.4                         3.5                1.67 (0.41--6.83)     1.28 (0.30--5.41)
   Social-economic status                                                                                                         
    High                                          1311   50/2200.8                      2.3                1.00                   
    Middle                                        722    28/1165.4                      2.4                1.06 (0.66--1.68)      
    Low                                           341    18/558.4                       3.2                1.42 (0.83--2.43)      
   Nugent score                                                                                                                   
    Normal                                        1093   42/1795.4                      2.3                1.00                  1.00
    Intermediate                                  339    6/544.2                        1.1                0.47 (0.20--1.11)     0.46 (0.20--1.09)
    BV                                            942    48/1585.0                      3.0                1.29 (0.86--1.96)     1.13 (0.74--1.72)
   HIV status                                                                                                                     
    Negative                                      2069   69/3387.4                      2.0                1.00                  1.00
    Positive                                      305    27/537                         5.0                2.47 (1.58--3.85)∗∗   2.34 (1.44--3.78)∗∗
   Syphilis serology                                                                                                              
    Negative                                      2300   92/3802.6                      2.4                1.00                  1.00
    Positive                                      74     4/122.0                        3.3                1.36 (0.50--3.69)     1.09 (0.39--3.01)

^\*^ *P* \< 0.05. ∗∗*P* \< 0.001.

                                                  *N*    Incident *T. vaginalis n*/PY   Incidence/100 py   Unadj.IRR 95% CI      Adj.IRR 95% CI
  ----------------------------------------------- ------ ------------------------------ ------------------ --------------------- ---------------------
  Overall                                         2374   96/3924.6                      2.4                                      
   HC use in last 12 months                                                                                                       
    No HC/no condom                               1054   45/1733.2                      2.60               1.00                  1.00
    DMPA only                                     664    15/1089.9                      1.4                0.53 (0.30--0.95)∗    0.54 (0.30--0.98)∗
    COC only                                      133    5/220.3                        2.3                0.87 (0.35--2.20)     1.02 (0.40--2.59)
    Implants only                                 32     4/56.0                         7.1                2.75 (1.00--7.65)∗    3.01 (1.07--8.49)∗
    Condoms only                                  491    27/825.2                       3.3                1.2 (0.78--2.03)      0.97 (0.57--1.64)
   Age                                                                                                                            
    \<20                                          165    11/277.7                       4.0                1.00                  1.00
    20--29                                        939    40/1566.3                      2.6                0.64 (0.33--1.26)     0.70 (0.34--1.43)
    30--39                                        951    37/1565.8                      2.4                0.60 (0.30--1.17)∗    0.57 (0.30--1.16)
    40+                                           319    8/514.8                        1.6                0.39 (0.16--0.98)∗∗   0.28 (0.11--0.73)∗∗
   Education                                                                                                                      
    None                                          102    8/172.3                        4.6                1.00                  1.00
    Primary                                       1426   67/2359.2                      2.8                0.610 (0.29--1.27)    0.63 (0.30--1.32)
    Secondary or more                             846    21/1393.0                      1.5                0.32 (0.14--0.73)∗∗   0.32 (0.14--0.74)∗∗
   Nonmarital sexual partners in last 12 months                                                                                   
    0                                             1835   64/3016.5                      2.1                1.00                  1.00
    1                                             506    30/851.7                       3.5                1.66 (1.07--2.56)     1.49 (0.92--2.42)
    2+                                            33     2/56.4                         3.5                1.67 (0.41--6.83)     1.26 (0.30--5.28)
   Social-economic status                                                                                                         
    High                                          1311   50/2200.8                      2.3                1.00                   
    Middle                                        722    28/1165.4                      2.4                1.06 (0.66--1.68)      
    Low                                           341    18/558.4                       3.2                1.41 (0.83--2.43)      
   Nugent score                                                                                                                   
    Normal                                        1093   42/1795.4                      2.3                1.00                  1.00
    Intermediate                                  339    6/544.2                        1.1                0.47 (0.20--1.11)     0.44 (0.19--1.05)
    BV                                            942    48/1585.0                      3.0                1.29 (0.86--1.96)     1.10 (0.72--1.69)
   HIV status                                                                                                                     
    Negative                                      2069   69/3387.4                      2.0                1.00                  1.00
    Positive                                      305    27/537                         5.0                2.40 (1.42--4.08)∗∗   2.38 (1.47--3.86)∗∗
   Syphilis serology                                                                                                              
    Negative                                      2300   92/3802.6                      2.4                1.00                  1.00
    Positive                                      74     4/122.0                        3.3                1.36 (0.50--3.69)     1.16 (0.42--3.20)

^\*^ *P* \< 0.05. ∗∗*P* \< 0.001.

                                                  *N*    Incident *T. vaginalis n*/PY   Incidence/100 py   Unadj.IRR 95% CI      Adj.IRR 95% CI
  ----------------------------------------------- ------ ------------------------------ ------------------ --------------------- ---------------------
  Overall                                         2374   96/3924.6                      2.4                                       
   HC use at baseline and follow-up                                                                                               
    Consistently used no method                   653    30/1071.7                      2.8                1.00                  1.00
    Consistently used HC                          483    15/789.1                       1.9                0.68 (0.36--1.26)     0.73 (0.39--1.40)
    Initiated HC use at follow-up                 244    9/402.7                        2.2                0.80 (0.38--1.68)     0.76 (0.36--1.69)
    Discontinued HC use at follow-up              215    3/350.6                        0.86               0.30 (0.09--1.00)∗    0.30 (0.09--0.99)∗
    Consistently used condoms                     217    12/365.9                       3.2                1.17 (0.60--2.29)     0.87 (0.42--1.79)
    Others                                        562    27/944.5                       2.8                1.02 (0.61--1.71)     0.81 (0.47--1.40)
   Age                                                                                                                            
    \<20                                          165    11/277.7                       4.0                1.00                  1.00
    20--29                                        939    40/1566.3                      2.6                0.64 (0.33--1.26)     0.71 (0.35--1.44)
    30--39                                        951    37/1565.8                      2.4                0.60 (0.30--1.17)     0.58 (0.28--1.17)
    40+                                           319    8/514.8                        1.6                0.39 (0.16--0.98)∗∗   0.28 (0.11--0.72)∗∗
   Education                                                                                                                      
    None                                          102    8/172.3                        4.6                1.00                  1.00
    Primary                                       1426   67/2359.2                      2.8                0.610 (0.29--1.27)    0.68 (0.32--1.43)
    Secondary or more                             846    21/1393.0                      1.5                0.32 (0.14--0.73)∗    0.34 (0.14--0.78)∗
   Nonmarital sexual partners in last 12 months                                                                                   
    0                                             1835   64/3016.5                      2.1                1.00                  1.00
    1                                             506    30/851.7                       3.5                1.66 (1.07--2.56)     1.47 (0.92--2.36)
    2+                                            33     2/56.4                         3.5                1.67 (0.41--6.83)     1.29 (0.31--5.37)
   Social-economic status                                                                                                         
    High                                          1311   50/2200.8                      2.3                1.00                   
    Middle                                        722    28/1165.4                      2.4                1.06 (0.66--1.68)      
    Low                                           341    18/558.4                       3.2                1.41 (0.83--2.43)      
   Nugent score                                                                                                                   
    Normal                                        1093   42/1795.4                      2.3                1.00                  1.00
    Intermediate                                  339    6/544.2                        1.1                0.47 (0.20--1.11)     0.46 (0.19--1.08)
    BV                                            942    48/1585.0                      3.0                1.29 (0.86--1.96)     1.14 (0.74--1.73)
   HIV Status                                                                                                                     
    Negative                                      2069   69/3387.4                      2.0                1.00                  1.00
    Positive                                      305    27/537                         5.0                2.40 (1.42--4.08)∗∗   2.36 (1.44--3.85)∗∗
   Syphilis serology                                                                                                              
    Negative                                      2300   92/3802.6                      2.4                1.00                  1.00
    Positive                                      74     4/122.0                        3.3                1.36 (0.50--3.69)     1.07 (0.39--2.94)

^\*^ *P* \< 0.05. ∗∗*P* \< 0.001.

                                                  *N*    Incident *T. vaginalis n*/PY   Incidence/100 py   Unadj.IRR 95% CI      Adj.IRR 95% CI
  ----------------------------------------------- ------ ------------------------------ ------------------ --------------------- ---------------------
  Overall                                         2374   96/3924.6                      2.4                                       
   HC use at baseline and follow-up                                                                                               
    Consistently used no method                   653    30/1071.7                      2.8                1.00                  1.00
    Consistently used DMPA                        359    9/582.9                        1.5                0.55 (0.26--1.16)     0.59 (0.28--1.26)
    Consistently used COCs                        50     2/84.2                         2.4                0.85 (0.20--3.55)     1.07 (0.25--4.56)
    Consistently used implants                    28     4/49.8                         8.0                2.87 (1.01--8.14)∗    3.13 (1.08--9.07)∗
    Other categories                              1284   51/2135.8                      2.4                0.85 (0.54--1.34)     0.70 (0.44--1.13)
   Age                                                                                                                            
    \<20                                          165    11/277.7                       4.0                1.00                  1.00
    20--29                                        939    40/1566.3                      2.6                0.64 (0.33--1.26)     0.65 (0.32--1.31)
    30--39                                        951    37/1565.8                      2.4                0.60 (0.30--1.17)     0.52 (0.26--1.06)
    40+                                           319    8/514.8                        1.6                0.39 (0.16--0.98)∗∗   0.26 (0.10--0.67)∗∗
   Education                                                                                                                      
    None                                          102    8/172.3                        4.6                1.00                  1.00
    Primary                                       1426   67/2359.2                      2.8                0.610 (0.29--1.27)    0.64 (0.30--1.38)
    Secondary or more                             846    21/1393.0                      1.5                0.32 (0.14--0.73)     0.34 (0.14--0.78)∗
   Nonmarital sexual partners in last 12 months                                                                                   
    0                                             1835   64/3016.5                      2.1                1.00                  1.00
    1                                             506    30/851.7                       3.5                1.66 (1.07--2.56)     1.61 (1.01--2.55)∗
    2+                                            33     2/56.4                         3.5                1.67 (0.41--6.83)     1.40 (0.33--5.77)
   Social-economic status                                                                                                         
    High                                          1311   50/2200.8                      2.3                1.00                   
    Middle                                        722    28/1165.4                      2.4                1.06 (0.66--1.68)      
    Low                                           341    18/558.4                       3.2                1.41 (0.83--2.43)      
   Nugent score                                                                                                                   
    Normal                                        1093   42/1795.4                      2.3                1.00                  1.00
    Intermediate                                  339    6/544.2                        1.1                0.47 (0.20--1.11)     0.45 (0.19--1.06)
    BV                                            942    48/1585.0                      3.0                1.29 (0.86--1.96)     1.09 (0.71--1.66)
   HIV status                                                                                                                     
    Negative                                      2069   69/3387.4                      2.0                1.00                  1.00
    Positive                                      305    27/537                         5.0                2.40 (1.42--4.08)     2.52 (1.56--4.08)∗∗
   Syphilis serology                                                                                                              
    Negative                                      2300   92/3802.6                      2.4                1.00                  1.00
    Positive                                      74     4/122.0                        3.3                1.36 (0.50--3.69)     1.07 (0.39--2.95)

^\*^ *P* \< 0.05. ∗∗*P* \< 0.001.

[^1]: Academic Editor: Cecile L. Tremblay
